Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.